Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic and transcriptomic landscape of HER2-low breast cancer.
Bansal R, Adeyelu T, Elliott A, Walker P, Bustos MA, Rodriguez E, Accordino MK, Meisel J, Gatti-Mays ME, Hsu E, Lathrop K, Kaklamani V, Oberley M, Sledge G, Sammons SL, Graff SL. Bansal R, et al. Among authors: graff sl. Breast Cancer Res Treat. 2024 Sep 20. doi: 10.1007/s10549-024-07495-4. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39302579
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Muquith M, et al. Among authors: graff sl. Nat Cancer. 2024 Jul;5(7):1121-1129. doi: 10.1038/s43018-024-00752-x. Epub 2024 Mar 25. Nat Cancer. 2024. PMID: 38528112
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H. Hsiehchen D, et al. Among authors: graff sl. Cancer Cell. 2024 Dec 9;42(12):1985-1987. doi: 10.1016/j.ccell.2024.10.017. Epub 2024 Nov 21. Cancer Cell. 2024. PMID: 39577419
PET/CT in Patients with Breast Cancer Treated with Immunotherapy.
Vaz SC, Graff SL, Ferreira AR, Debiasi M, de Geus-Oei LF. Vaz SC, et al. Among authors: graff sl. Cancers (Basel). 2023 May 5;15(9):2620. doi: 10.3390/cancers15092620. Cancers (Basel). 2023. PMID: 37174086 Free PMC article. Review.
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines.
Groheux D, Vaz SC, Poortmans P, Mann RM, Ulaner GA, Cook GJR, Hindié E, Pilkington Woll JP, Jacene H, Rubio IT, Vrancken Peeters MJ, Dibble EH, de Geus-Oei LF, Graff SL, Cardoso F. Groheux D, et al. Among authors: graff sl. Breast. 2024 Dec;78:103806. doi: 10.1016/j.breast.2024.103806. Epub 2024 Sep 12. Breast. 2024. PMID: 39303572 Free PMC article. Review.
53 results